Finance

Lists
ALT:NASDAQ
Altimmune Inc
$3.11
-4.01%
(-0.13) 1D
$3.12
+0.37% (+0.011)
After hours
Closed: Aug 28, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ALT...
Open
$3.21
High
$3.23
Low
$3.06
Mkt. cap
604.95M
Avg. vol.
4.66M
Volume
3.19M
52-wk high
$6.44
52-wk low
$2.56
EPS
-$0.78
Beta
0.27
Shares outstanding
194.52M
No. of employees
57
Open
$3.21
High
$3.23
Low
$3.06
Mkt. cap
604.95M
Avg. vol.
4.66M
Volume
3.19M
52-wk high
$6.44
52-wk low
$2.56
EPS
-$0.78
Beta
0.27
Shares outstanding
194.52M
No. of employees
57
About Altimmune Inc
CEOJerry Durso
Employees57
Founded1997
HeadquartersGaithersburg, Maryland, United States
SectorBiotechnology
Websitealtimmune.com
Analyst ratings
Based on 6 analysts giving stock ratings to ALT in the past 3 months
Strong buy
Buy
5
Hold
1
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for ALT in the last 3 months.
Highest
Current $3.11
$28.00 (+800.32%)
Average
$19.50 (+527.01%)
Lowest
$10.00 (+221.54%)
Analyst
Recommendation
Action
Price target
Projected
Date
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$20.00
+543.1%
08/17/2026
Eliana Merle
Barclays
Buy
Maintained
$20.00
+543.1%
08/13/2026
Unknown Analyst
Jefferies
Buy
Maintained
$28.00
+800.3%
08/13/2026
Andy Hsieh
William Blair
Hold
Reiterated
-
-
08/12/2026
Srikripa Devarakonda
Truist Financial
Buy
Maintained
-
-
07/29/2026
Thomas Smith
Leerink Partners
Buy
Maintained
$10.00
+221.5%
07/28/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$11.00
+253.7%
05/14/2026
Corinne Johnson
Goldman Sachs
Hold
Upgraded
$2.50
-19.6%
04/24/2026
William Wood
B. Riley Securities
Buy
Maintained
$13.00
+318%
03/06/2026
Boris Peaker
JonesTrading
Buy
Initiated
$7.00
+125.1%
02/13/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
5.00K
26.00K
-
-
Cost of goods sold
14.96M
18.41M
15.48M
17.86M
Cost of revenue
14.96M
18.41M
15.48M
17.86M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.90M
10.51M
8.05M
7.57M
Operating expense
5.90M
10.51M
8.05M
7.57M
Total operating expenses
20.86M
28.92M
23.54M
25.43M
Operating income
-20.86M
-28.89M
-23.54M
-25.43M
Other non operating income
-86.00K
-27.00K
-152.00K
-25.00K
EBT including unusual items
-19.01M
-27.36M
-22.56M
-22.82M
EBT excluding unusual items
-19.01M
-27.36M
-21.85M
-22.02M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-19.01M
-27.36M
-22.56M
-22.82M
Net profit margin
-380,280.00%
-105,223.08%
-
-
Earnings per share
-0.21
-0.27
-0.18
-0.12
Interest and investment income
2.43M
2.44M
2.90M
4.53M
Interest expense
-495.00K
-876.00K
-1.07M
-1.10M
Net interest expenses
1.93M
1.56M
1.83M
3.43M
Depreciation and amortization charges
-
-
-
-
EBITDA
-20.83M
-28.87M
-23.51M
-25.41M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps